A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

被引：2

作者：

Christofyllakis, Konstantinos ^{[1
]}

Poeschel, Viola ^{[1
]}

Altmann, Bettina ^{[2
]}

Maurer, Stephanie ^{[1
]}

Lesan, Vadim ^{[1
]}

Bittenbring, Joerg ^{[1
]}

Kos, Igor Age ^{[1
]}

Kaddu-Mulindwa, Dominic ^{[1
]}

Abdi, Zanir ^{[1
]}

Fleser, Octavian ^{[1
]}

Altmeyer, Sarah ^{[1
]}

Neuendorff, Nina Rosa ^{[3
]}

Nickelsen, Maike ^{[4
]}

Held, Gerhard ^{[5
]}

Dreyling, Martin ^{[6
]}

Zettl, Florian ^{[7
]}

Buske, Christian ^{[8
]}

Lenz, Georg ^{[9
]}

Glass, Bertram ^{[10
]}

Chapuy, Bjoern ^{[11
]}

Schmitz, Norbert ^{[9
]}

Vassilakopoulos, Theodoros ^{[12
]}

Ott, German ^{[13
,14
]}

Siebert, Reiner ^{[15
,16
]}

Viardot, Andreas ^{[15
,16
]}

Scherer, Florian ^{[17
]}

Schmitz, Roland ^{[18
]}

Rosenwald, Andreas ^{[19
]}

Hellwig, Dirk ^{[20
]}

Loeffler, Markus ^{[2
]}

Stilgenbauer, Stephan ^{[21
]}

Thurner, Lorenz ^{[1
]}

Bewarder, Moritz ^{[1
]}

Ziepert, Marita ^{[2
]}

机构：

[1] Saarland Univ, Med Ctr, Dept Internal Med Oncol Hematol Clin Immunol & Rh, Homburg, Germany

[2] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany

[3] Univ Hosp Essen, Dept Haematol & Stem Cell Transplantat, Essen, Germany

[4] Onkol Lerchenfeld, Hamburg, Germany

[5] Westpfalz Klinikum, Dept Internal Med 1, Kaiserslautern, Germany

[6] LMU Univ Hosp, Dept Internal Med 3, Munich, Germany

[7] Klinikum Traunstein, Dept Hematol & Oncol, Traunstein, Germany

[8] Univ Hosp Ulm, Inst Expt Canc Res, Ulm, Germany

[9] Univ Hosp Muenster, Dept Med A Hematol Oncol & Pneumol, Munster, Germany

[10] Asklepios Klin St Georg, Dept Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany

[11] Charite, Med Ctr Berlin, Dept Hematol Oncol & Tumor Immunol, Campus Benjamin Franklin, Berlin, Germany

[12] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol & Bone Marrow Transplantat, Athens, Greece

[13] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany

[14] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[15] Ulm Univ, Inst Human Genet, Ulm, Germany

[16] Ulm Univ, Med Ctr, Ulm, Germany

[17] Univ Freiburg, Fac Med, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany

[18] Univ Hosp Giessen, Inst Pathol Mol Cytol & Funct Genom, Giessen, Germany

[19] Julius Maximilians Univ Wurzburg, Inst Pathol, Wurzburg, Germany

[20] Univ Hosp Regensburg, Dept Nucl Med, Regensburg, Germany

[21] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179200

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[41] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Luscan, Gerald
Paccagnella, Luisa
Patel, Krish
BLOOD, 2023, 142
[42] Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial
Belada, David
Christensen, Jacob Haaber
Drott, Kristina
Snauwaert, Sylvia
Brody, Joshua
Narkhede, Mayur
Offner, Fritz
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
Clausen, Michael Roost
BLOOD, 2021, 138
[43] First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab plus Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Nowakowski, Grzegorz S.
Duell, Johannes
Kopeckova, Katerina
Trneny, Marek
Pott, Christiane
Khouja, Mouhamad
Burke, John M.
Waldron-Lynch, Maeve
Wagner, Steve
Mukhopadhyay, Amitava
Blair, Derek
Belada, David
BLOOD, 2022, 140 : 3731 - 3732
[44] First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab plus Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Belada, David
Kopeckova, Katerina
Burgues, Juan Miguel Bergua
Stevens, Don
Andre, Marc
Persona, Ernesto Perez
Pichler, Petra
Staber, Philipp B.
Trneny, Marek
Brackertz, Bettina
Shah, Neha
Sporchia, Andrea
Burke, John M.
Nowakowski, Grzegorz S.
BLOOD, 2021, 138
[45] A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Czuczman, Myron S.
Trneny, Marek
Davies, Andrew
Rule, Simon
Linton, Kim M.
Wagner-Johnston, Nina
Gascoyne, Randy D.
Slack, Graham W.
Brousset, Pierre
Eberhard, David A.
Hernandez-Ilizaliturri, Francisco J.
Salles, Gilles
Witzig, Thomas E.
Zinzani, Pier Luigi
Wright, George W.
Staudt, Louis M.
Yang, Yandan
Williams, P. Mickey
Lih, Chih-Jian
Russo, Jacqueline
Thakurta, Anjan
Hagner, Patrick
Fustier, Pierre
Song, Dale
Lewis, Ian D.
CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4127 - 4137
[46] Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Viardot, A.
Goebeler, M.
Pfreundschuh, M.
Adrian, N.
Libicher, M.
Hess, G.
Zettl, F.
Neumann, S.
Degenhard, E.
Stieglmaier, J.
Zhang, A.
Nagorsen, D.
Bargou, R. C.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 33 - 33
[47] A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma
Martin, Peter
Bartlett, Nancy L.
Rivera, Ildefonso Ismael Rodriguez
Revuelta, Maria
Chavez, Julio C.
Reagan, John L.
Smith, Sonali M.
LaCasce, Ann S.
Zhang, Lei
Zhai, Merry
Wu, Chengqing
Leonard, John P.
Cerchietti, Leandro
BLOOD, 2017, 130
[48] Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
Abramson, Jeremy S.
Ku, Matthew
Hertzberg, Mark
Huang, Hui-Qiang
Fox, Christopher P.
Zhang, Huilai
Yoon, Dok Hyun
Kim, Won-Seog
Abdulhaq, Haifaa
Townsend, William
Herbaux, Charles
Zaucha, Jan M.
Zhang, Qing-Yuan
Chang, Hung
Liu, Yanyan
Cheah, Chan Yoon
Ghesquieres, Herve
Simko, Stephen
Orellana-Noia, Victor
Ta, Richard
Relf, James
Dixon, Mark
Kallemeijn, Martine
Mulvihill, Estefania
Huang, Huang
Lundberg, Linda
Gregory, Gareth P.
LANCET, 2024, 404 (10466): : 1940 - 1954
[49] A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) us subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL)
Younes, Anas
Zinzani, Pier Luigi
Sehn, Laurie Helen
Johnson, Peter W. M.
Gascoyne, Randy D.
Ahmedi, Tahamtan
Bellew, Kevin M.
Verrneulen, Jessica
Zhuang, Sen Hong
Sun, Stevan
Staudt, Louis M.
Wilson, Wyndham Hopkins
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[50] B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase trial.
Nowakowski, Grzegorz S.
Belada, David
Molina, Lysianne
Kopeckova, Katerina
Laribi, Kamel
del Campo Garcia, Raquel
Coiffier, Bertrand
Jurczak, Wojciech
Rummel, Mathias J.
Hess, Georg
Rosenwald, Andreas
Winderlich, Mark
Korolkiewicz, Roman
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →